ASI has officially joined the ZYTOMICS family
ZYTOMICS announces the acquisition of Applied Spectral Imaging (ASI)
Berlin, Germany, and Carlsbad, CA – August 6, 2025 – ZYTOMICS, a leading provider of clinical cancer diagnostic solutions, announces the acquisition of Applied Spectral Imaging, a market leader in advanced digital imaging for pathology and cytogenetics laboratories.
Leading the way in biomedical imaging for over three decades, ASI offers a comprehensive product portfolio for brightfield, fluorescence and spectral imaging. Its multiple applications address diagnostic needs across numerous domains, including karyotyping, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). With a steadfast focus on delivering advanced diagnostics and user-centric solutions, ASI stands at the forefront of technology in digital pathology and cytogenetics.
“This strategic acquisition reflects our continued commitment to delivering comprehensive, end-to-end solutions that advance the frontiers of scientific discovery and diagnostics” said Zytomics’ CEO, Bastian Eirich. “We are excited for this next chapter which will allow us to integrate ASI’s innovative imaging technologies with our high-performance reagents, to create a powerful synergy designed to benefit our customers in meaningful ways.”
This milestone marks an exciting new chapter for ZYTOMICS and ASI - one that reflects a strong commitment to accelerate innovation and deliver state-of-the art solutions for diagnostics labs.
“By combining ASI’s strength in imaging and analysis with ZYTOMICS’ reagents, automation and analytics, we are creating a robust, end-to-end offering in pathology and cytogenetics that will accelerate product and technology innovation while strengthening customer value and service” said Limor Shiposh, CEO at ASI. “And through it all, we will continue to deliver the trusted products, flexibility and open system philosophy that make ASI a partner of choice” Limor added.
Together, ZYTOMICS and ASI bring a comprehensive offering of diagnostic solutions for cytogenetics and pathology laboratories. Because Every Diagnosis Counts.
ZYTOMICS
Headquartered in Berlin, ZYTOMICS is a combination of three established and longstanding European cancer diagnostics companies: Zytomed Systems, ZytoVision and Diagomics. The company’s offering includes reagents, automation and analytics with a focus on IHC, in situ hybridization (ISH) and next generation sequencing (NGS) diagnostics. ZYTOMICS is certified in accordance with Regulation (EU) 2017/746 (IVDR) for a significant portion of its Class C product portfolio.
For more information about ZYTOMICS, visit www.zytomics.com/ or E-mail bestellung-de@zytomics.com
Applied Spectral Imaging (ASI)
For over 30 years, ASI has led the field in biomedical imaging, delivering advanced platforms for pathology and cytogenetics laboratories in over 80 countries. The company’s solutions - HiPath Pro, PathFusion, HiBand, HiFISH, CytoPower and HiSKY - streamline the diagnostic workflow, from image acquisition through analysis, reporting, and integration to any laboratory information system. ASI serves key markets worldwide through a combination of direct engagement and a global distribution network.
For more information about ASI, visit www.spectral-imaging.com or E-mail sales@spectral-imaging.com
